Novavax Earns $125 Million Milestone as Sanofi Starts Phase 3 Trial
Novavax says it earned a $125 million milestone as Sanofi began a Phase 3 flu-COVID vaccine trial.
Related stories
European session market picture: S&P 500 -0.84%, Nasdaq 100 -1.95%; EUR/USD +0.15%, WTI +1.61%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.84 percent, Nasdaq futures is down 1.95 percent, Dow futures is up 0.18 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 09:01 AM UTC
AMD, Nvidia, Micron and Arm shares fall
AMD fell 6.5%, Nvidia 2.5%, Micron 3.7% and Arm 7.5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
BlackRock Raises Combined Stake in Tryg Above 5%
BlackRock's combined holding in Tryg has risen above 5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
Jiangxi Copper falls more than 6% again intraday
M impact | EQUITY | Oct 30, 2026, 08:57 AM UTC
Court Accepts Bankruptcy Liquidation Application Against CNG Weihai
A court accepted a bankruptcy liquidation application against CNG Weihai on Oct. 29, 2026.
M impact | EQUITY | Oct 30, 2026, 08:56 AM UTC
FOKUS 3-BP Reports Record Third-Quarter Profit
M impact | EQUITY | Oct 30, 2026, 08:51 AM UTC